Preliminary study on CLAG regime in the treatment of patients with refractory and relapsed acute myeloid leukemia

Abstract

Objective To observe the efficacy and adverse events of CLAG regime for the treatment of patients with refractory and relapsed acute myeloid leukemia (AML). Methods Efficacy and adverse events in patients with refractory and relapsed AML who were treated with one course of CLAG from January 2014 to January 2015 were retrospectively analyzed. Results The patients included 6 males and 6 females, with a median age of 35 years old (range 14-68 years old). According to FAB subtype, there were 8 patients with M2, 1 with M1, 1 with M4, 1 with M5, and 1 with hybrid acute leukemia respectively. Six patients were identified as molecular subtype abnormalities, including 3 in AML1/ETO fusion and 3 in FLT3-ITD mutation. There were 7 patients with refractory and 5 with relapsed, and the median previous chemotherapy courses were 5(1-15). After one course of GLAG regime, 10 patients achieved hematological complete response, 1 case died, 1 case unremitted. 11 patients had grade 4 neutropenia and thrombocytopenia and infection with different sites without treatment-related mortality. Three patients received allo-hematopoietic stem cell transplantation. Conclusions CLAG regime is effective and well tolerable in patients with refractory and relapsed AML. Allo-hematopoietic stem cell transplantation should be performed as soon as possible when patients achieved complete response. Key words: Leukemia, myeloid, acute; CLAG regime; Refractory; Relapsed